Relay Therapeutics Stock Probability of Future Stock Price Finishing Under 4.65

RLAY Stock  USD 4.86  0.11  2.32%   
Relay Therapeutics' future price is the expected price of Relay Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Relay Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Relay Therapeutics Backtesting, Relay Therapeutics Valuation, Relay Therapeutics Correlation, Relay Therapeutics Hype Analysis, Relay Therapeutics Volatility, Relay Therapeutics History as well as Relay Therapeutics Performance.
For more information on how to buy Relay Stock please use our How to Invest in Relay Therapeutics guide.
  
Price To Sales Ratio is likely to drop to 50.19 in 2024. Price Earnings Ratio is likely to drop to -4.14 in 2024. Please specify Relay Therapeutics' target price for which you would like Relay Therapeutics odds to be computed.

Relay Therapeutics Target Price Odds to finish below 4.65

The tendency of Relay Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to drop to $ 4.65  or more in 90 days
 4.86 90 days 4.65 
roughly 2.32
Based on a normal probability distribution, the odds of Relay Therapeutics to drop to $ 4.65  or more in 90 days from now is roughly 2.32 (This Relay Therapeutics probability density function shows the probability of Relay Stock to fall within a particular range of prices over 90 days) . Probability of Relay Therapeutics price to stay between $ 4.65  and its current price of $4.86 at the end of the 90-day period is about 1.52 .
Given the investment horizon of 90 days the stock has the beta coefficient of 3.89 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Relay Therapeutics will likely underperform. Additionally Relay Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Relay Therapeutics Price Density   
       Price  

Predictive Modules for Relay Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Relay Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.244.8012.40
Details
Intrinsic
Valuation
LowRealHigh
1.999.5917.19
Details
Naive
Forecast
LowNextHigh
0.094.6712.26
Details
13 Analysts
Consensus
LowTargetHigh
22.0424.2226.88
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Relay Therapeutics. Your research has to be compared to or analyzed against Relay Therapeutics' peers to derive any actionable benefits. When done correctly, Relay Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Relay Therapeutics.

Relay Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Relay Therapeutics is not an exception. The market had few large corrections towards the Relay Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Relay Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Relay Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.84
β
Beta against Dow Jones3.89
σ
Overall volatility
0.95
Ir
Information ratio -0.07

Relay Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Relay Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Relay Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Relay Therapeutics generated a negative expected return over the last 90 days
Relay Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 25.55 M. Net Loss for the year was (341.97 M) with profit before overhead, payroll, taxes, and interest of 1.38 M.
Relay Therapeutics currently holds about 1.05 B in cash with (300.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 98.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Disposition of 19864 shares by Peter Rahmer of Relay Therapeutics at 6.47 subject to Rule 16b-3

Relay Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Relay Stock often depends not only on the future outlook of the current and potential Relay Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Relay Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding122.6 M
Cash And Short Term Investments750.1 M

Relay Therapeutics Technical Analysis

Relay Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Relay Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Relay Therapeutics. In general, you should focus on analyzing Relay Stock price patterns and their correlations with different microeconomic environments and drivers.

Relay Therapeutics Predictive Forecast Models

Relay Therapeutics' time-series forecasting models is one of many Relay Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Relay Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Relay Therapeutics

Checking the ongoing alerts about Relay Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Relay Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Relay Therapeutics generated a negative expected return over the last 90 days
Relay Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 25.55 M. Net Loss for the year was (341.97 M) with profit before overhead, payroll, taxes, and interest of 1.38 M.
Relay Therapeutics currently holds about 1.05 B in cash with (300.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Over 98.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Disposition of 19864 shares by Peter Rahmer of Relay Therapeutics at 6.47 subject to Rule 16b-3

Additional Tools for Relay Stock Analysis

When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.